DNA 标记与 RNA 控制:急性髓系白血病的新线索
From DNA marks to RNA control: A new clue to acute myeloid leukemia
一项新研究发现,TET2 和 AGO2 在急性髓系白血病中的作用机制,揭示了表观遗传调控与 RNA 控制之间的联系。降低 AGO2 水平可减缓白血病细胞的生长,表明 AGO2 可能是潜在的治疗靶点。
Acute myeloid leukemia (AML) is an aggressive blood cancer in which abnormal, immature cells build up in the bone marrow, disrupting the production of healthy blood cells. Now, a new study, led by Dr. José Luis Sardina's group at the Josep Carreras Leukaemia Research Institute (IJC), examines how two systems that help control normal blood cell development are connected: the chemical marks on DNA and the regulation of RNA, which carries instructions for making proteins. The work is published in the journal Science Advances.
TET2 is one of the genes frequently mutated in AML. It produces a protein that regulates DNA methylation, a type of chemical marking that helps control gene activity without altering the DNA sequence. This is part of a broader system known as epigenetics. Although TET2 plays an important role in blood cell development, how it directs the genetic programs that guide cell identity is still not fully understood.
Dr. Aleksey Lazarenkov is the first author of the investigation, which studied cells as they developed into macrophages, a type of immune cell. The team mapped where TET2 acts along the DNA and examined DNA methylation, gene activity and DNA organization. They identified several gene regulatory regions associated with TET2, including one within the AGO2 gene.
Linking epigenetic regulation to RNA control in blood cell development
The AGO2 gene produces the AGO2 protein, which is involved in RNA interference, a process that helps cells control the fate of RNA molecules, including whether they are broken down or used to make proteins. The researchers found that TET2 binds to regulatory regions within the AGO2 gene, where it helps remove DNA methylation marks and promote AGO2 expression. This reveals how epigenetic regulation can influence the machinery that controls RNA.
Reducing AGO2 levels accelerated the acquisition of macrophage identity and altered processes involved in cell growth, metabolism and inflammatory responses. These findings suggest that AGO2 contributes to the coordination of myeloid cell identity with the cellular programs that support cell growth, prompting the team to investigate whether leukemia cells also depend on this protein.
"Interestingly, our findings suggest that AGO2 helps coordinate the acquisition of myeloid cell identity with the programs that support cell growth. This led us to ask whether leukemia cells might exploit this newly identified function of AGO2 to sustain their uncontrolled growth," explains Lazarenkov, first author of the study.
Implications for acute myeloid leukemia
Using international patient databases, the team found increased DNA methylation in a region controlling the AGO2 gene in AML cases with TET2 mutations. This suggests that AGO2 regulation is disrupted in these patients. AGO2 expression and DNA methylation patterns were also associated with patient survival and other clinical features. These findings raise the possibility that these measurements could help assess the likely course of the disease, although further studies are needed to establish their usefulness as biomarkers.
The team then reduced AGO2 levels in leukemia cells from patients with AML before transplanting the modified cells into mice. Working with Dr. Pablo Menendez, group leader at the Josep Carreras Institute, they found that these cells were substantially less able to establish and sustain leukemia. These findings provide functional evidence that AGO2 contributes to leukemia development and suggest that it could be a potential treatment target. However, whether targeting AGO2 would be safe or effective in patients remains unknown.
"These findings open new avenues for investigating how AGO2 supports leukemia development and whether this dependency could be exploited therapeutically. More work is needed to understand the underlying mechanisms and establish the potential relevance of this discovery for patients," says Sardina, senior author of the study.
Publication details
Aleksey Lazarenkov et al., TET2-driven activation of AGO2 links epigenetic remodeling to myeloid commitment and leukemia, Science Advances (2026). DOI: 10.1126/sciadv.aee5701
Journal information: Science Advances
Clinical categories
Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: From DNA marks to RNA control: A new clue to acute myeloid leukemia (2026, November 4) retrieved 4 November 2026 from https://medicalxpress.com/news/2026-11-dna-rna-clue-acute-myeloid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
来源:Medical Xpress · medicalxpress.com